NanoString Technologies, Inc. (NSTG) Issues FY17 Earnings Guidance

NanoString Technologies, Inc. (NASDAQ:NSTG) updated its FY17 earnings guidance on Thursday. The company provided EPS guidance of ($1.99-1.86) for the period, compared to the Thomson Reuters consensus EPS estimate of ($2.10). The company issued revenue guidance of $109-112 million, compared to the consensus revenue estimate of $110.55 million.

NSTG has been the topic of a number of research reports. Robert W. Baird dropped their target price on shares of NanoString Technologies from $14.00 to $12.00 and set an outperform rating on the stock in a report on Friday. Cowen and Company restated a buy rating on shares of NanoString Technologies in a report on Friday, July 14th. Zacks Investment Research cut shares of NanoString Technologies from a buy rating to a hold rating in a report on Saturday, August 12th. BidaskClub cut shares of NanoString Technologies from a sell rating to a strong sell rating in a report on Friday, July 28th. Finally, Janney Montgomery Scott cut shares of NanoString Technologies from a buy rating to a neutral rating in a report on Thursday, October 12th. Three equities research analysts have rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating to the company’s stock. The company currently has an average rating of Hold and a consensus price target of $17.25.

Shares of NanoString Technologies, Inc. (NSTG) traded down $1.99 during mid-day trading on Friday, hitting $7.79. 1,260,000 shares of the stock were exchanged, compared to its average volume of 277,696. NanoString Technologies, Inc. has a 1 year low of $7.32 and a 1 year high of $23.45. The company has a current ratio of 4.22, a quick ratio of 3.74 and a debt-to-equity ratio of 0.93.

NanoString Technologies (NASDAQ:NSTG) last announced its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.45) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.56) by $0.11. NanoString Technologies had a negative net margin of 44.24% and a negative return on equity of 227.21%. The business had revenue of $27.02 million for the quarter, compared to analyst estimates of $26.27 million. During the same quarter in the prior year, the business earned ($0.51) EPS. NanoString Technologies’s quarterly revenue was up 12.9% on a year-over-year basis. analysts expect that NanoString Technologies, Inc. will post -2.26 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This news story was first published by Community Financial News and is owned by of Community Financial News. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at

About NanoString Technologies

NanoString Technologies, Inc develops, manufactures and sells intuitive products that unlock scientifically valuable and clinically actionable biologic information from minute amounts of tissue. The Company is engaged in the development, manufacture and commercialization of instruments, consumables and services for profiling the activity of hundreds of genes and proteins simultaneously from a single tissue sample.

What are top analysts saying about NanoString Technologies Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for NanoString Technologies Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit